Evaluation of Rifalazil in a Combination Treatment Regimen as an Alternative to Isoniazid-Rifampin Therapy in a Mouse Tuberculosis Model
The newer rifamycin, rifalazil (RLZ) (previously known as KRM-1648), has been shown in prior experiments to be a highly potent drug against Mycobacterium tuberculosis. In this report, we studied the efficacy of RLZ in combination with pyrazinamide (PZA) and ethambutol (EMB) in a long-term in vivo ex...
সংরক্ষণ করুন:
| প্রকাশিত: | Antimicrob Agents Chemother |
|---|---|
| প্রধান লেখক: | , , |
| বিন্যাস: | Artigo |
| ভাষা: | Inglês |
| প্রকাশিত: |
American Society for Microbiology (ASM)
2000
|
| বিষয়গুলি: | |
| অনলাইন ব্যবহার করুন: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC101623/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11036043/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.44.11.3167-3168.2000 |
| ট্যাগগুলো: |
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|